Developer docs
API playgroundTry for free, no card

Search company profiles

Protagonist Therapeutics

Full company profile

uuid0000q55

Namestring
Protagonist Therapeutics
Legal namestring
Protagonist Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-to-commercial biopharmaceutical company developing orally-stable peptide therapeutics for rare and prevalent diseases historically addressed by injectable antibodies. The company was founded in 2008 and incubated at the Institute for Molecular Biosciences at the University of Queensland in Brisbane, Australia, with corporate headquarters now in Newark, California. Its proprietary Vectrix™ molecular design platform combines computational virtual libraries, structure-based and phage display screening, oral stability assays, and formulation know-how to engineer peptides against challenging targets including cytokines, cytokine receptors, integrins, GPCRs, and ion channels.

The company's commercial product is ICOTYDE (icotrokinra / JNJ-2113), the first and only targeted oral IL-23 receptor therapy, FDA-approved in March 2026 for moderate-to-severe plaque psoriasis in patients 12 and older, and developed under an exclusive worldwide license with Johnson & Johnson. Its second late-stage asset, rusfertide (PTG-300), is a first-in-class hepcidin mimetic for polycythemia vera with FDA Priority Review and a Q3 2026 PDUFA date, partnered worldwide with Takeda. Earlier-stage wholly-owned programs include PN-881 (oral IL-17 antagonist, Phase 1) and PN-477sc and PN-477oral (GLP-1/GIP/GCG agonists for obesity, Phase 1 starts in 2026).

Protagonist operates an asset-light, partnership-driven business model: it does not sell product directly. Johnson & Johnson and Takeda handle global commercialization, regulatory strategy (for rusfertide), and pricing. Protagonist's revenue is generated through licensing milestones and tiered royalties—Icotrokinra economics include 6-10% royalties on global net sales plus up to $580M in additional milestones; rusfertide economics include 14-29% royalties on worldwide net sales and up to $975M in milestone payments following Protagonist's 2026 opt-out of 50:50 U.S. profit-sharing. Reported full-year 2025 revenue was $46.0M (vs. $434.4M in 2024, reflecting milestone timing), with $646M in cash and marketable securities providing runway through at least 2028.

Short descriptiontext

Protagonist Therapeutics is a biopharmaceutical company that develops orally-stable peptide therapeutics. It generates revenue through licensing milestones and royalties from partnered programs including the FDA-approved psoriasis drug ICOTYDE (Johnson & Johnson) and the polycythemia vera candidate rusfertide (Takeda).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNewark, United States
HQ citystring
Newark
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, oral peptide drugs, biopharmaceutical development, inflammatory disease treatments, rare disease therapies
Industry2 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Peptide Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Icotrokinra Royalties
TypeLicensing Royalties
Description

Johnson & Johnson commercializes icotrokinra (ICOTYDE) globally. Protagonist receives tiered royalties of 6-10% on global net sales, with potential for up to $580 million in additional regulatory and sales milestones. The $50 million milestone was triggered upon FDA approval in March 2026.

morningstar.com
2Rusfertide Milestones and Royalties
TypeLicensing Royalties
Description

Protagonist opted out of 50:50 U.S. profit-sharing with Takeda, receiving $200 million upfront and $200 million upon FDA approval, with total potential of $475 million tied to the opt-out election. Additionally eligible for up to $975 million in milestone payments and tiered royalties of 14-29% on worldwide net sales.

stocktitan.net
3Milestone Payments
TypeLicensing Royalties
Description

episodic milestone payments from partners for regulatory achievements, clinical trial completions, and commercial launches. Q4 2025 revenue was $46 million, significantly lower than $434.4 million in prior year due to variable milestone timing.

newswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Protagonist Therapeutics is a clinical-to-commercial biopharmaceutical company that discovers and develops orally-stable peptide therapeutics for diseases currently addressed by injectable antibodies. The company applies a proprietary peptide technology platform spanning computational design, structure-based libraries, oral stability assays, and novel formulation approaches to engineer peptide drugs against challenging targets including cytokines, cytokine receptors, integrin, GPCRs, and ion channels. Its lead commercialized asset is ICOTYDE (icotrokinra), an oral IL-23 receptor antagonist for plaque psoriasis commercialized by Johnson & Johnson, and its second lead asset is rusfertide, a first-in-class hepcidin mimetic for polycythemia vera being commercialized by Takeda.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 55-70% of patients achieved clear or almost clear skin (PASI 90) at weeks 16 and 24 in Phase 3 trials
+3 more records
Product and service2 records
1ICOTYDE (icotrokinra)
CategoryOral Peptide Therapeutics - Immunology/Dermatology
Description

ICOTYDE (icotrokinra, also known as JNJ-2113) is a once-daily oral IL-23 receptor antagonist peptide co-developed with Johnson & Johnson (Janssen Biotech) and FDA-approved in March 2026 for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older. It is the first and only targeted oral IL-23 receptor therapy and is commercialized globally by Johnson & Johnson under a 2017 licensing and collaboration agreement.

2Rusfertide (PTG-300)
CategoryOral/Subcutaneous Peptide Therapeutics - Hematology/Rare Disease
Description

Rusfertide (PTG-300) is a first-in-class hepcidin mimetic peptide therapeutic in development for polycythemia vera (a rare chronic blood disorder affecting approximately 150,000 U.S. patients). It is partnered with Takeda Pharmaceutical under a January 2024 worldwide license and collaboration agreement and has received FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations. Protagonist exercised its opt-out right in 2026 to receive $200M upfront and $200M upon FDA approval, with up to $775M in additional milestones and 14-29% tiered royalties on worldwide net sales.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Worldwide license and collaboration agreement entered January 2024 for rusfertide (PTG-300), a first-in-class hepcidin mimetic for polycythemia vera. Protagonist led development through Phase 3; Takeda manages U.S. regulatory strategy. Protagonist exercised opt-out from 50:50 profit-sharing in 2026, receiving $200M upfront and $200M upon FDA approval, with potential for up to $775M additional milestones and 14-29% royalties. FDA granted Priority Review with PDUFA date Q3 2026.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

Licensing and collaboration agreement entered in 2017 for oral IL-23 receptor antagonist (icotrokinra/JNJ-2113). Janssen holds exclusive worldwide rights to develop and commercialize. Protagonist eligible for $50M milestone (received March 2026), up to $580M in additional milestones, and 6-10% tiered royalties on global net sales. ICOTYDE received FDA approval March 2026 for moderate-to-severe plaque psoriasis. J&J projects $5-10 billion market opportunity.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Protagonist Therapeutics

Biopharmaceutical Peptide Therapeuticsprotagonist-inc.com

Protagonist Therapeutics is a biopharmaceutical company that develops orally-stable peptide therapeutics. It generates revenue through licensing milestones and royalties from partnered programs including the FDA-approved psoriasis drug ICOTYDE (Johnson & Johnson) and the polycythemia vera candidate rusfertide (Takeda).

What Protagonist Therapeutics does

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-to-commercial biopharmaceutical company developing orally-stable peptide therapeutics for rare and prevalent diseases historically addressed by injectable antibodies. The company was founded in 2008 and incubated at the Institute for Molecular Biosciences at the University of Queensland in Brisbane, Australia, with corporate headquarters now in Newark, California. Its proprietary Vectrix™ molecular design platform combines computational virtual libraries, structure-based and phage display screening, oral stability assays, and formulation know-how to engineer peptides against challenging targets including cytokines, cytokine receptors, integrins, GPCRs, and ion channels.

The company's commercial product is ICOTYDE (icotrokinra / JNJ-2113), the first and only targeted oral IL-23 receptor therapy, FDA-approved in March 2026 for moderate-to-severe plaque psoriasis in patients 12 and older, and developed under an exclusive worldwide license with Johnson & Johnson. Its second late-stage asset, rusfertide (PTG-300), is a first-in-class hepcidin mimetic for polycythemia vera with FDA Priority Review and a Q3 2026 PDUFA date, partnered worldwide with Takeda. Earlier-stage wholly-owned programs include PN-881 (oral IL-17 antagonist, Phase 1) and PN-477sc and PN-477oral (GLP-1/GIP/GCG agonists for obesity, Phase 1 starts in 2026).

Protagonist operates an asset-light, partnership-driven business model: it does not sell product directly. Johnson & Johnson and Takeda handle global commercialization, regulatory strategy (for rusfertide), and pricing. Protagonist's revenue is generated through licensing milestones and tiered royalties—Icotrokinra economics include 6-10% royalties on global net sales plus up to $580M in additional milestones; rusfertide economics include 14-29% royalties on worldwide net sales and up to $975M in milestone payments following Protagonist's 2026 opt-out of 50:50 U.S. profit-sharing. Reported full-year 2025 revenue was $46.0M (vs. $434.4M in 2024, reflecting milestone timing), with $646M in cash and marketable securities providing runway through at least 2028.

Protagonist Therapeutics firmographics

Firmographics
Name
Protagonist Therapeutics
Legal name
Protagonist Therapeutics, Inc.
Website
https://protagonist-inc.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
101–250 employees
Short description
Protagonist Therapeutics is a biopharmaceutical company that develops orally-stable peptide therapeutics. It generates revenue through licensing milestones and royalties from partnered programs including the FDA-approved psoriasis drug ICOTYDE (Johnson & Johnson) and the polycythemia vera candidate rusfertide (Takeda).
Ownership category
akta.pro rank

Protagonist Therapeutics industry classification

Industry
Product category
Biopharmaceutical Peptide Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Peptide therapeutics
  • Oral peptide drugs
  • Biopharmaceutical development
  • Inflammatory disease treatments
  • Rare disease therapies

Where Protagonist Therapeutics is headquartered

Location

Headquarters

HQ city
Newark
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Protagonist Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Icotrokinra Royalties: Johnson & Johnson commercializes icotrokinra (ICOTYDE) globally. Protagonist receives tiered royalties of 6-10% on global net sales, with potential for up to $580 million in additional regulatory and sales milestones. The $50 million milestone was triggered upon FDA approval in March 2026.
  2. Rusfertide Milestones and Royalties: Protagonist opted out of 50:50 U.S. profit-sharing with Takeda, receiving $200 million upfront and $200 million upon FDA approval, with total potential of $475 million tied to the opt-out election. Additionally eligible for up to $975 million in milestone payments and tiered royalties of 14-29% on worldwide net sales.
  3. Milestone Payments: episodic milestone payments from partners for regulatory achievements, clinical trial completions, and commercial launches. Q4 2025 revenue was $46 million, significantly lower than $434.4 million in prior year due to variable milestone timing.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Protagonist Therapeutics product offering

Product offering

Core offering

Protagonist Therapeutics is a clinical-to-commercial biopharmaceutical company that discovers and develops orally-stable peptide therapeutics for diseases currently addressed by injectable antibodies. The company applies a proprietary peptide technology platform spanning computational design, structure-based libraries, oral stability assays, and novel formulation approaches to engineer peptide drugs against challenging targets including cytokines, cytokine receptors, integrin, GPCRs, and ion channels. Its lead commercialized asset is ICOTYDE (icotrokinra), an oral IL-23 receptor antagonist for plaque psoriasis commercialized by Johnson & Johnson, and its second lead asset is rusfertide, a first-in-class hepcidin mimetic for polycythemia vera being commercialized by Takeda.

Differentiator

Problem solved

Functional benefit

Products and services

  • ICOTYDE (icotrokinra) ICOTYDE (icotrokinra, also known as JNJ-2113) is a once-daily oral IL-23 receptor antagonist peptide co-developed with Johnson & Johnson (Janssen Biotech) and FDA-approved in March 2026 for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older. It is the first and only targeted oral IL-23 receptor therapy and is commercialized globally by Johnson & Johnson under a 2017 licensing and collaboration agreement.
  • Rusfertide (PTG-300) Rusfertide (PTG-300) is a first-in-class hepcidin mimetic peptide therapeutic in development for polycythemia vera (a rare chronic blood disorder affecting approximately 150,000 U.S. patients). It is partnered with Takeda Pharmaceutical under a January 2024 worldwide license and collaboration agreement and has received FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations. Protagonist exercised its opt-out right in 2026 to receive $200M upfront and $200M upon FDA approval, with up to $775M in additional milestones and 14-29% tiered royalties on worldwide net sales.

Quantifiable outcome

  • 55-70% of patients achieved clear or almost clear skin (PASI 90) at weeks 16 and 24 in Phase 3 trials
  • +3 more outcomes

Companies that use Protagonist Therapeutics

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Protagonist Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Protagonist Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship.

  • Takeda PharmaceuticalsflagshipStrategic or Co-development Partner · 1 January 2024Worldwide license and collaboration agreement entered January 2024 for rusfertide (PTG-300), a first-in-class hepcidin mimetic for polycythemia vera. Protagonist led development through Phase 3; Takeda manages U.S. regulatory strategy. Protagonist exercised opt-out from 50:50 profit-sharing in 2026, receiving $200M upfront and $200M upon FDA approval, with potential for up to $775M additional milestones and 14-29% royalties. FDA granted Priority Review with PDUFA date Q3 2026.
  • Johnson & Johnson (Janssen Biotech)flagshipStrategic or Co-development Partner · 1 January 2017Licensing and collaboration agreement entered in 2017 for oral IL-23 receptor antagonist (icotrokinra/JNJ-2113). Janssen holds exclusive worldwide rights to develop and commercialize. Protagonist eligible for $50M milestone (received March 2026), up to $580M in additional milestones, and 6-10% tiered royalties on global net sales. ICOTYDE received FDA approval March 2026 for moderate-to-severe plaque psoriasis. J&J projects $5-10 billion market opportunity.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Protagonist Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Protagonist Therapeutics social profiles

Digital presence

Protagonist Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Protagonist Therapeutics leadership team

Management profile

Number of profiles

Profiles16 records

Protagonist Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Protagonist Therapeutics funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Protagonist Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protagonist Therapeutics

What does Protagonist Therapeutics do?

Protagonist Therapeutics is a clinical-to-commercial biopharmaceutical company that discovers and develops orally-stable peptide therapeutics for diseases currently addressed by injectable antibodies. The company applies a proprietary peptide technology platform spanning computational design, structure-based libraries, oral stability assays, and novel formulation approaches to engineer peptide drugs against challenging targets including cytokines, cytokine receptors, integrin, GPCRs, and ion channels. Its lead commercialized asset is ICOTYDE (icotrokinra), an oral IL-23 receptor antagonist for plaque psoriasis commercialized by Johnson & Johnson, and its second lead asset is rusfertide, a first-in-class hepcidin mimetic for polycythemia vera being commercialized by Takeda.

Is Protagonist Therapeutics a public or private company?

Protagonist Therapeutics is a public company. It is classified as public and is currently operating.

When was Protagonist Therapeutics founded?

Protagonist Therapeutics was founded in 2008. It employs 101 to 250 people.

Where is Protagonist Therapeutics based?

Protagonist Therapeutics is headquartered in Newark, United States, in the North America region.

How does Protagonist Therapeutics make money?

Three revenue lines are on record. Icotrokinra Royalties are the primary driver. The others are rusfertide Milestones and Royalties and milestone Payments.

Does Protagonist Therapeutics have an API?

No public API is recorded for Protagonist Therapeutics.

What industry is Protagonist Therapeutics in?

Protagonist Therapeutics's product category is Biopharmaceutical Peptide Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldProtagonist Therapeutics, Inc. $PTGX Holdings Raised by Bessemer Group Inc.Bessemer Group increased its stake in Protagonist Therapeutics by 141.6% in Q3, buying 73,748 shares. Insiders sold 186,347 shares in the last 90 days, and the stock opened at $124.67. Analysts rate the stock a Buy with a consensus price target of $166.67.Investing.comProtagonist Therapeutics CMO Molina sells $338,798 in sharesProtagonist Therapeutics CMO Arturo Molina sold 2,718 shares on November 16, 2026, for $338,798 to cover tax withholding. The stock trades near $124.67, down 7.6% weekly but up 43% year-to-date. The company also reported FDA approval for Mimrylo and plans for a Phase 1 oral PN-477 study in 2027.Investing.comProtagonist Therapeutics at Jefferies Global Healthcare Conference: partner-led growthProtagonist Therapeutics presented at Jefferies' Global Healthcare Conference, stating it has two approved drugs (ICOTYDE and MIMRYLO) commercialized via partnerships with Johnson & Johnson and Takeda, without its own sales force. The company reported over $500 million in pending milestone payments and a $551.69 million trailing revenue, with ICOTYDE exceeding 20,000 prescriptions.American Banking and Market NewsProtagonist Therapeutics, Inc. $PTGX Stock Purchased by Calamos Advisors LLCCalamos Advisors increased its stake in Protagonist Therapeutics by 60.6% in Q3, buying 7,225 shares to hold 19,156 shares worth $2.7 million. The company reported Q3 EPS of $3.07, beating estimates, and insiders sold 217,868 shares over 90 days. Analysts rate the stock a Buy with an average price target of $166.67.TradingViewHC Wainwright & Co. maintains Protagonist Therapeutics at Buy, raises price target to $221 from $170HC Wainwright & Co. maintained Protagonist Therapeutics at Buy and raised its price target to $221 from $170, a 30% increase. The target implies a 63.4% upside from the Nov 5 close of $135.26. Recent analyst price targets range from $160 to $190.TradingViewProtagonist Therapeutics 3Q 2026: Revenue $274.41M, EPS $3.07 — 10-Q SummaryProtagonist Therapeutics reported Q3 2026 revenue of $274.41M and net income of $220.02M, up 5,723.6% and 659.3% year-over-year. The gain was driven by Takeda opt-out and milestone payments, including $266.6M from MIMRYLO and ICOTYDE approvals.YahooProtagonist Therapeutics: Q3 Earnings SnapshotProtagonist Therapeutics reported third-quarter net income of $220 million, or $3.07 per share, on Thursday. The results beat analyst estimates of $2.58 per share and revenue of $267 million. Revenue of $274.4 million also exceeded forecasts.Simply Wall StProtagonist Therapeutics (PTGX) Could Be 18% Undervalued As Earnings Expectations RiseProtagonist Therapeutics faces upcoming quarterly earnings with consensus of $2.58 per share and higher revenue. The stock trades at 111.9x earnings, far above the 28.1x fair ratio, while a fair value of $174.69 suggests undervaluation. The company's oral peptide programs and $300 million buyback program are key to justifying the gap.Investing.comProtagonist Therapeutics earnings in spotlight after FDA winsProtagonist Therapeutics will report Q3 earnings Thursday, with analysts expecting $2.39 per share on $241.46 million revenue. The report will focus on royalty revenue from Mimrylo, a polycythemia vera treatment approved in August, and updates on PN-881. The company's stock trades at $140.24, up 86% from its 52-week low.Investing.comUBS reiterates Buy on Protagonist Therapeutics stock citing Mimrylo launch progressUBS reiterated a Buy rating and $184 price target on Protagonist Therapeutics after a medical conference, citing Mimrylo's FDA approval for erythrocytosis in polycythemia vera. The stock has surged 83.5% over the past year, though it appears overvalued relative to fair value. UBS expects gradual community adoption.